title: The antimalarial ferroquine: from bench to clinic.
abstract: Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.
authors: Unité de Catalyse et Chimie du Solide, CNRS UMR 8181, Université Lille Nord de France. christophe.biot@univ-lille1.fr
authors: C
authors: C
authors: Biot
authors: F
authors: F
authors: Nosten
authors: L
authors: L
authors: Fraisse
authors: D
authors: D
authors: Ter-Minassian
authors: J
authors: J
authors: Khalife
authors: D
authors: D
authors: Dive
mesh_terms: D000634:Aminoquinolines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D002738:Chloroquine / Q000737:chemistry / Q000494:pharmacology; D017322:Clinical Trials, Phase II as Topic; D004351:Drug Resistance; D005296:Ferrous Compounds / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D016780:Malaria, Vivax / Q000188:drug therapy*; D000075163:Metallocenes; D010963:Plasmodium falciparum / Q000187:drug effects; D010966:Plasmodium vivax / Q000187:drug effects
chemical_list: D000634:Aminoquinolines; D000962:Antimalarials; D005296:Ferrous Compounds; D000075163:Metallocenes; D002738:Chloroquine; C479230:ferroquine